Curcuminoid treatment for knee osteoarthritis: A randomized double-blind placebo-controlled trial

Phytotherapy Research

Volumn 28, Issue 11, 2014, Pages 1625-1631

  Panahi, Yunes ^a   Rahimnia, Ali Reza ^a   Sharafi, Mojtaba ^a   Alishiri, Gholamhossein ^a   Saburi, Amin ^a   Sahebkar, Amirhossein ^b,c  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Arthritis; Curcumin; Herbal medicine; Pain

Indexed keywords

BLACK PEPPER EXTRACT; CURCUMINOID; NAPROXEN; PLANT MEDICINAL PRODUCT; POLYPHENOL DERIVATIVE; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; CURCUMIN;

ADULT; AGE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY MASS; CARTILAGE CELL; CELL PROTECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENDER; HUMAN; JOINT STIFFNESS; KNEE OSTEOARTHRITIS; MALE; PAIN; PARALLEL DESIGN; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; VISUAL ANALOG SCALE; WESTERN ONTARIO AND MCMASTER UNIVERSITIES OSTEOARTHRITIS INDEX; AGED; DOUBLE BLIND PROCEDURE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PAIN MEASUREMENT; PHYTOTHERAPY;

AGED; ANTI-INFLAMMATORY AGENTS; CURCUMIN; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PAIN; PAIN MEASUREMENT; PHYTOTHERAPY; PILOT PROJECTS;

EID: 84908220474     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.5174     Document Type: Article

References (53)

1. Abramson SB. 2008. Nitric oxide in inflammation and pain associated with osteoarthritis. Arthritis Res Ther 10: S2.
2. Ak T, Gulcin I. 2008. Antioxidant and radical scavenging properties of curcumin. Chem Biol Interact 174: 27-37.
3. Badria FA, El-Farahaty T, Shabana AA, Hawas SA, El-Batoty MF. 2002. Boswellia-curcumin preparation for treating knee osteoarthritis: A clinical evaluation. Alt Compl Ther 8: 341-348.
4. Baraf HS, Fuentealba C, Greenwald M, et al. 2007. Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial. J Rheumatol 34: 408-420.
5. Basaran S, Guzel R, Seydaoglu G, Guler-Uysal F. 2010. Validity, reliability, and comparison of the WOMAC osteoarthritis index and Lequesne algofunctional index in Turkish patients with hip or knee osteoarthritis. Clin Rheumatol 29: 749-756.
6. Belcaro G, Cesarone MR, Dugall M, et al. 2010. Product-evaluation registry of Meriva(R), a curcumin-phosphatidylcholine complex, for the complementary management of osteoarthritis. Panminerva Med 52: 55-62.
7. Belcaro G, Hosoi M, Pellegrini L, et al. 2014. A controlled study of a lecithinized delivery system of curcumin (meriva®) to alleviate the adverse effects of cancer treatment. Phytother Res 28: 444-450.
8. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. 1988. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 15:1833-1840.
9. Buhrmann C, Mobasheri A, Busch F, et al. 2011. Curcumin modulates nuclear factor kappaB (NF-kappaB)-mediated inflammation in human tenocytes in vitro: role of the phosphatidylinositol 3-kinase/ Akt pathway. J Biol Chem286: 28556-28566.
10. Buhrmann C, Mobasheri A, Matis U, Shakibaei M. 2010. Curcumin mediated suppression of nuclear factor-kappaB promotes chondrogenic differentiation of mesenchymal stem cells in a highdensity co-culturemicroenvironment. Arthritis Res Ther 12: R127.
11. Chandran B, Goel A. 2012. A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother Res 26: 1719-1725.
12. Chopra A, Saluja M, Tillu G, et al. 2013. Ayurvedic medicine offers a good alternative to glucosamine and celecoxib in the treatment of symptomatic knee osteoarthritis: a randomized, double-blind, controlled equivalence drug trial. Rheumatology 52: 1408-1417.
13. Chowdhury TT, Salter DM, Bader DL, Lee DA. 2008. Signal transduction pathways involving p38 MAPK, JNK, NFkappaB and AP-1 influences the response of chondrocytes cultured in agarose constructs to IL-1beta and dynamic compression. Inflamm Res 57: 306-313.
14. Clutterbuck AL, Mobasheri A, Shakibaei M, Allaway D, Harris P. 2009. Interleukin-1beta-induced extracellular matrix degradation and glycosaminoglycan release is inhibited by curcumin in an explant model of cartilage inflammation. Ann N Y Acad Sci 1171: 428-435.
15. Csaki C, Mobasheri A, Shakibaei M. 2009. Synergistic chondroprotective effects of curcumin and resveratrol in human articular chondrocytes: inhibition of IL-1beta-induced NF-kappaB-mediated inflammation and apoptosis. Arthritis Res Ther 11: R165.
16. Fehri B, Ahmed MK, Aiache JM. 2011. The relaxant effect induced by Allium sativum L. bulb aqueous extract on rat isolated trachea. Pharmacogn Mag 7: 14-18.
17. Franchignoni F, Salaffi F, Giordano A, Ciapetti A, Carotti M, Ottonello M. 2012. Psychometric properties of self-administered Lequesne Algofunctional Indexes in patients with hip and knee osteoarthritis: an evaluation using classical test theory and Rasch analysis. Clin Rheumatol 31: 113-121.
18. Gupta SC, Kismali G, Aggarwal BB. 2013a. Curcumin, a component of turmeric: from farm to pharmacy. Biofactors 39: 2-13.
19. Gupta SC, Patchva S, Aggarwal BB. 2013b. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J 15: 195-218.
20. Im HJ, Li X, Muddasani P, et al. 2008. Basic fibroblast growth factor accelerates matrix degradation via a neuro-endocrine pathway in human adult articular chondrocytes. J Cell Physiol 215: 452-463.
21. Kang MJ, Cho JY, Shim BH, Kim DK, Lee J. 2009. Bioavailability enhancing activities of natural compounds from medicinal plant. J Med Plants Res 3: 1204-1211.
22. Kawasaki T, Inoue K, Ushiyama T, Fukuda S. 1998. Assessment of the American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the knee. Ryumachi [Rheumatism] 38: 2-5.
23. Khajuria A, Thusu N, Zutshi U. 2002. Piperine modulates permeability characteristics of intestine by inducing alterations in membrane dynamics: influence on brush border membrane fluidity, ultrastructure and enzyme kinetics. Phytomedicine 9: 224-231.
24. Kim KH, Lee EN, Park JK, et al. 2012. Curcumin attenuates TNF-induced expression of intercellular adhesion molecule-1, vascular cell adhesion molecule-1 and proinflammatory cytokines in human endometriotic stromal cells. Phytother Res 26: 1037-1047.
25. Konstantinidis GA, Aletras VH, Kanakari KA, Natsis K, Bellamy N, Niakas D. 2013. Comparative validation of the WOMAC osteoarthritis and Lequesne algofunctional indices in Greek patients with hip or knee osteoarthritis. Qual Life Res. doi: 10.1007/s11136-013-0490-x.
26. Kulkarni RR, Patki PS, Jog VP, Gandage SG, Patwardhan B. 1991. Treatment of osteoarthritis with a herbomineral formulation: a double-blind, placebocontrolled, cross-over study. J Ethnopharmacol33: 91-95.
27. Lee KK, Omiya Y, Yuzurihara M, Kase Y, Kobayashi H. 2013. Antispasmodic effect of shakuyakukanzoto extract on experimental muscle cramps in vivo: role of the active constituents of Glycyrrhizae radix. J Ethnopharmacol 145: 286-293.
28. Mathy M, Sanchez C, Priem F, Henrotin Y. 2007. Curcumin inhibits interleukin-6,-8, nitric oxide and prostaglandin E2 synthesis by bovine chondrocytes. Osteoarthritis Cartilage 15(Suppl C): C115.
29. Mathy-Hartert M, Jacquemond-Collet I, Priem F, Sanchez C, Lambert C, Henrotin Y. 2009. Curcumin inhibits proinflammatory mediators and metalloproteinase-3 production by chondrocytes. Inflamm Res 58: 899-908.
30. Menon VP, Sudheer AR. 2007. Antioxidant and anti-inflammatory properties of curcumin. Adv Exp Med Biol 595: 105-125.
31. Mohammadi A, Sahebkar A, Iranshahi M, et al. 2013. Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial. Phytother Res 27: 374-379.
32. Na LX, Li Y, Pan HZ, et al. 2013. Curcuminoids exert glucoselowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial. Mol Nutr Food Res 57: 1569-1577.
33. Nadrian H, Moghimi N, Nadrian E, et al. 2012. Validity and reliability of the Persian versions ofWOMACOsteoarthritis Index and Lequesne Algofunctional Index. Clinical Rheumatol 31: 1097-1102.
34. Neogi T. 2013. The epidemiology and impact of pain in osteoarthritis. Osteoarthritis Cartilage 21: 1145-1153.
35. Panahi Y, Sahebkar A, Amiri M, et al. 2012a. Improvement of sulphur mustard-induced chronic pruritus, quality of life and antioxidant status by curcumin: results of a randomised, doubleblind, placebo-controlled trial. Br J Nutr 108: 1272-1279.
36. Panahi Y, Sahebkar A, Parvin S, Saadat A. 2012b. A randomized controlled trial on the anti-inflammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications. Ann Clin Biochem 49: 580-588.
37. Panahi Y, Saadat A, Beiraghdar F, Sahebkar A. 2014a. Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: A randomized double-blind placebo-controlled trial. Phytother Res. doi: 10.1002/ptr.5149.
38. Panahi Y, Saadat A, Beiraghdar F, Hosseini Nouzari SM, Jalalian HR, Sahebkar A. 2014b. Antioxidant effects of bioavailabilityenhanced curcuminoids in patients with solid tumors: A randomized double-blind placebo-controlled trial. J Funct Foods 6: 615-622.
39. Sahebkar A. 2010. Molecular mechanisms for curcumin benefits against ischemic injury. Fertility Steril 94: e75-76.
40. Sahebkar A. 2013. Are Curcuminoids Effective C-Reactive Protein-Lowering Agents in Clinical Practice? Evidence from a Meta-Analysis. Phytother Res. doi: 10.1002/ptr.5045.
41. Sahebkar A. 2014a. Low-density lipoprotein is a potential target for curcumin: Novel mechanistic insights. Basic Clin Pharmacol Toxicol. doi: 10.1111/bcpt.12212.
42. Sahebkar A. 2014b. Curcuminoids for the management of hypertriglyceridaemia. Nat Rev Cardiol 11: 2.
43. Sahebkar A, Mohammadi A, Atabati A, et al. 2013. Curcuminoids Modulate Pro-Oxidant-Antioxidant Balance but not the Immune Response to Heat Shock Protein 27 and Oxidized LDL in Obese Individuals. Phytother Res 27: 1883-1887.
44. Shakibaei M, John T, Schulze-Tanzil G, Lehmann I, Mobasheri A. 2007. Suppression of NF-kappaB activation by curcumin leads to inhibition of expression of cyclo-oxygenase-2 and matrix metalloproteinase-9 in human articular chondrocytes: Implications for the treatment of osteoarthritis. Biochem Pharmacol 73: 1434-1445.
45. Shehzad A, Lee J, Lee YS. 2013a. Curcumin in various cancers. Biofactors 39: 56-68.
46. Shehzad A, Rehman G, Lee YS. 2013b. Curcumin in inflammatory diseases. Biofactors 39: 69-77.
47. Shoba G, Joy D, Joseph T,MajeedM, Rajendran R, Srinivas PS. 1998. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 64: 353-356.
48. Suri P, Morgenroth DC, Hunter DJ. 2012. Epidemiology of osteoarthritis and associated comorbidities. PM R 4: S10-19.
49. Sutipornpalangkul W, Morales NP, Harnroongroj T. 2009. Free radicals in primary knee osteoarthritis. J Med Assoc Thai 92(Suppl 6): S268-274.
50. Towheed TE, Judd MJ, Hochberg MC, Wells G. 2003. Acetaminophen for osteoarthritis. The Cochrane database of systematic reviews, CD004257.
51. Wu CW, Morrell MR, Heinze E, et al. 2005. Validation of American College of Rheumatology classification criteria for knee osteoarthritis using arthroscopically defined cartilage damage scores. Semin Arthritis Rheum 35: 197-201.
52. Yin W, Zhang X, Shi X, Li Y. 2012. Curcumin protects SH-SY5Y cells from oxidative stress by up-regulating HO-1 via Phosphatidylinositol 3 Kinase/Akt/Nrf-2 and down-regulating HO-2. Mol Neurodegener 7: S14.
53. Yu D, Yuan Y, Jiang L, et al. 2013. Anti-inflammatory effects of essential oil in Echinacea purpurea L. Pakistan J PharmSci 26: 403-408.